Experts Matter. Find Yours.
Connect for media, speaking, professional opportunities & more.
ChristianaCare ranked as 81st best hospital in the United States and the only health system in Delaware to make the list For the fifth consecutive year, ChristianaCare has earned a spot in Newsweek’s exclusive list of the World’s Best Hospitals – United States, recognized for consistently being at the forefront in care, research and innovation. “Receiving this honor year after year is a testament to the work ChristianaCare caregivers do each day to create health together so that every person can flourish,” said ChristianaCare President & CEO Janice E. Nevin, M.D., MPH. “At its core our mission is a simple, yet profound, one. We take care of people. And I am so proud of everyone in this organization for what five-straight years of being called one of the World’s Best Hospitals says about the exceptional quality of the care we provide.” Headquartered in Wilmington, Del., ChristianaCare ranked 81st in the United States in the annual list that ranks 2,300 hospitals in 28 countries. “ChristianaCare has gained a global reputation thanks to our unwavering focus to provide expert, high-quality care,” said Kert Anzilotti, M.D., MBA, chief medical officer at ChristianaCare. “This award belongs to all our caregivers, who continuously seek new knowledge, are true to their word and are committed to delivering exceptional care to every patient we serve.” Compiled by Newsweek and the global data firm Statista, the lists are based on the following data sources: Recommendations from tens of thousands of doctors, health care professionals and managers across the world. The survey asked participants to recommend hospitals in their own country as well as in other countries. The survey did not permit recommendations of the health professional’s own hospital. Patient surveys originating from publicly available data that included areas such as their general satisfaction with the hospital and their satisfaction with their medical care. Hospital quality metrics such as data on the quality of care for specific treatments, data on hygiene measures and patient safety, and data on clinician-patient ratios. The Patient Reported Outcome Measures (PROM) surveys, which are standardized, validated questionnaires completed by patients to measure their well-being and quality of life. The recognition by Newsweek echoes other quality recognitions that ChristianaCare has received during the past 12 months: For the third consecutive year, Healthgrades named ChristianaCare one of America’s 50 Best Hospitals for 2023. Healthgrades also ranked ChristianaCare as one of America’s 50 Best Hospitals for five service lines: cardiac care, coronary intervention, joint replacement, spine surgery and gastrointestinal surgery. For the seventh consecutive year, the College of Healthcare Information Management Executives named ChristianaCare a Most Wired Health Care Technology Leader. U.S. News & World Report rated ChristianaCare as the No. 42 hospital in the nation for obstetrics and gynecology and a High Performing Hospital for Maternity. U.S. News & World Report also rated ChristianaCare as high-performing in orthopedics. For the second consecutive year, Forbes ranked ChristianaCare as one of the Best Employers for Diversity and Inclusion in the United States. The Human Rights Campaign Foundation gave ChristianaCare’s Christiana Hospital and Wilmington Hospital the top score in the Human Rights Campaign Foundation’s most recent Healthcare Equality Index.
Comprehensive Sleep Wellness Center Opens on Newark Campus
More than 70 million Americans suffer from sleep-related problems. To address this growing need, ChristianaCare has opened a new comprehensive sleep wellness center in the Medical Arts Pavilion II on the ChristianaCare Newark Campus. The ChristianaCare Sleep Wellness Center, accredited by the American Academy of Sleep Medicine, is an outpatient program that provides expert diagnosis and treatment of sleep disorders. The nearly 5,000 square foot, seven-bed facility builds on the success of ChristianaCare’s previous sleep diagnostic center, now incorporating clinical care and diagnostic testing at the same site. The center is staffed by board-certified sleep medicine specialists who provide in-lab and at-home sleep testing, as well as a behavioral health specialist who offers cognitive behavioral therapy for insomnia. The center offers onsite and virtual appointments. “At the ChristianaCare Sleep Wellness Center, we offer the full range of sleep care services in one place, with the expertise to help people with all kinds of sleep disorders,” said Shilpa Kauta, M.D., medical director of the ChristianaCare Sleep Wellness Center. “Sleep disorders affect members of every race, socioeconomic class and age group, but despite the high prevalence of sleep disorders, many people remain undiagnosed and untreated,” she said. National surveys show that more than 60 percent of adults have never been asked about the quality of their sleep by a physician. “It’s important for people to know that if they have problems related to sleeping, they should talk to their doctor about it, or call us at the Sleep Wellness Center. Sleep disorders can affect overall health—and they are often very treatable.” The Sleep Wellness Center provides expert, multidisciplinary diagnosis and care for every kind of sleep problem, including: Obstructive sleep apnea. Restless leg syndrome. Narcolepsy. Parasomnias, such as sleepwalking. As part of the ChristianaCare team, the expert staff at the Sleep Wellness Center coordinates with disease-based programs at ChristianaCare to integrate sleep services into cardiac care, weight loss surgery and renal transplant care. They also partner with surgeons to manage hypoglossal nerve stimulation therapy, a major advancement in obstructive sleep apnea treatment. Patients at the Sleep Wellness Center undergo a personal sleep history, medical background and physical examination. If appropriate, a polysomnography (sleep study) may be ordered to monitor and record brain waves, heart rate, blood oxygen level, breathing and eye movements. Poor Sleep Health is a National Problem According to the National Institutes of Health, of the 70 million Americans suffering from sleep-related problems, more than 50% are likely to have a chronic disorder, such as insomnia, obstructive sleep apnea, restless leg syndrome and narcolepsy. People who suffer from sleep disorders are also more likely to have chronic diseases like hypertension, diabetes, depression, obesity and even cancer. The impact on American life and economy is enormous as sleep deprivation and untreated sleep disorders are estimated to cost over $100 billion annually in lost productivity, medical expenses, sick leave, property and environmental damage. “With information collected through testing, our sleep experts can determine the source of a sleep problem and begin a treatment plan to help patients improve their quality of life,” Kauta said. The address and phone number of the new center: ChristianaCare Sleep Wellness Center 4735 Ogletown Stanton Rd. Suite 2210 Newark, DE 19713 302-623-0610
Aston University teams up with eye care provider to reduce NHS patient backlog
Aston University and Eye Docs Ltd enter Knowledge Transfer Partnership to establish new shared-care regimes for eye care patients The new model will help patients access Eye Docs surgeons It will help reduce NHS waiting lists, outpatient clinic backlogs, improve patient care and deliver profits of over £8.8 million Aston University has teamed up with private ophthalmic services clinic, Eye Docs, to undertake a 32-month Knowledge Transfer Partnership (KTP), to help clear NHS surgery waiting-lists and outpatient backlogs. In the West Midlands, average NHS waiting times have increased to over 12 months due to the impact of the Covid-19 pandemic, with waiting list contracts ranging from 100 to 1,500 patients. A cross-disciplinary team from Aston University’s School of Optometry and Aston Business School will work with West Midlands-based company Eye Docs to create a ‘shared-care’ model as part of the KTP. A KTP is a three-way collaboration between a business, an academic partner and a highly qualified researcher, known as a KTP associate. The working model will encompass clinical optometry and management science expertise to identify which patient appointments could be undertaken in community practices and which need to be seen by Eye Docs surgeons. It is hoped this way of working will also help reduce pressure on the NHS - creating a more efficient and cost-effective model that will benefit all stakeholders from patients to clinicians. The Aston University team will be led by Professor Shehzad Naroo, professor of optometry, who brings expertise in leading multidisciplinary groups and managing projects that improve eye care service delivery. Professor Naroo has a long history of working with private clinics to improve delivery of eye care, increasing efficiency and widening the role of private clinics to support the NHS. He will be supported by Professor Prasanta Dey, professor in operations and information management, whose research interests are in project management, service operations management, supply chain management and applications of multi-criteria decision making in industry. Completing the team will be Dr Yang Zhao, senior lecturer in operations and information management, whose research interests are in business model design, digital business models, platform business models, digital innovation, digital healthcare and digitalisation in aging societies. Professor Shehzad Naroo, professor of optometry at Aston University, said: “It is a privilege to be involved in this KTP, which will enable Eye Docs to increase patient numbers to fully utilise theatre capacity by receiving more surgical referrals from local optometrists. “We’re thrilled to be able to help Eye Docs to offer community-based services to patients and help to reduce the burden on the NHS.” Professor Shah, consultant ophthalmic surgeon and co-owner of Eye Docs, said: “This partnership will allow us to adopt the latest research and expertise from a world-leading academic institute to develop new patient pathways and shared-care regimes, enabling us to grow our business and profitability, develop new services and improve patient care. “Working with a multidisciplinary team of clinical and business experts from Aston University will help us to achieve the aims of this project.”
• Leading scientist wins €2.2 million ERC Advanced Grant • The five-year project will explore early dementia interventions through understanding how an aquaporin water channel regulates glymphatic clearance • ERC Advanced Grant funding is amongst the most prestigious and competitive of the EU funding schemes. A world leading scientist in the College of Health and Life Sciences at Aston University has been awarded a €2.2 million ERC Advanced Grant to understand how the movement of a protein known as aquaporin-4 in the brain can help slow cognitive decline. The FORTIFY project, which will run for five years, is led by Professor Roslyn Bill in the School of Biosciences. She will apply her discovery of the movement of aquaporin-4 to understand how the cleaning mechanism in the brain works during sleep. The research will focus on how aquaporin-4 controls the glymphatic system, which is the mechanism that allows us to clear waste products from our brains while we sleep. Her hypothesis is that the movement of aquaporin-4 in the brain changes the effectiveness of this cleansing mechanism - which lessens as people age. A greater understanding of this process could lead to an early intervention treatment that could slow the onset of dementia, such as Alzheimer’s and Parkinson’s Diseases. ERC Advanced Grant funding is amongst the most prestigious and competitive of the EU funding schemes, providing researchers with the opportunity to pursue ambitious, curiosity-driven projects that could lead to major scientific breakthroughs. Professor Bill said: “Every three seconds someone in the world develops dementia and there is no cure. I want to stop that from happening. By understanding the molecular mechanisms of brain waste clearance, we have an opportunity to develop medicines that can slow the onset of dementia, very much in the same way that statins are prescribed to control heart disease”. Roslyn Bill discovered that the water channel protein aquaporin-4 increases the permeability of brain cells to water after a brain or spinal cord injury. Around 60 million people a year suffer such injuries following falls or accidents. For example, after a skiing accident in the French Alps in 2013, Michael Schumacher suffered a severe head injury. He was placed in a medically induced coma and underwent several surgeries to treat his injuries. Until now doctors have only been able to manage the symptoms of brain injury (swelling on the brain) through interventions that may require surgery. Professor Bill and her team are due to start clinical trials in summer 2023, to test a method to stop the swelling from happening in its tracks, building on her discoveries. Roslyn’s new ERC-funded project, FORTIFY, will focus on how aquaporin-4 controls fluid flow in the healthy, uninjured brain. In this round of Advanced Grants, the European Research Council (ERC) is awarding €544 million to 218 outstanding research leaders across Europe, as part of the Horizon Europe programme. The grants will support cutting edge research in a wide range of fields, from medicine and physics to social sciences and humanities. The grant is awarded to established, leading researchers with a proven track-record of significant research achievements over the past decade. The funding will enable the researchers to explore their most innovative and ambitious ideas. Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth, said: “ERC grants are a top recognition and a significant commitment from our best researchers. The €544 million funding puts our 218 research leaders, together with their teams of postdoctoral fellows, PhD students and research staff, in pole position to push back the boundaries of our knowledge, break new ground and build foundations for future growth and prosperity in Europe” Maria Leptin, ERC President, added: "These new ERC Advanced Grantees are a testament to the outstanding quality of research carried out across Europe. I am especially pleased to see such a high number of female researchers in this competition and that they are increasingly successful in securing funding. “We look forward to seeing the results of the new projects in the years to come, with many likely to lead to breakthroughs and new advances.”
ChristianaCare Named one of Mogul’s Top 100 Companies with Inclusive Benefits
Recognition affirms ChristianaCare’s deep commitment to inclusion and diversity ChristianaCare has been recognized as one of the Top 100 Companies with Inclusive Benefits by Mogul, a diversity recruitment platform that partners with the world’s fastest-growing companies to attract and advance top diverse talent. ChristianaCare was recognized for both its “diverse hiring practices” and “progressive workplace resources.” “At ChristianaCare, we embrace diversity and show respect to everyone, and we reinforce these behaviors through purposeful actions that enable all our caregivers to serve our neighbors with love and excellence,” said Neil Jasani, M.D., MBA, FACEP, chief people officer at ChristianaCare. “By offering a wide array of inclusive benefits, we more fully support our caregivers in their commitment to being exceptional today and even better tomorrow.” The honor by Mogul is the latest recognition for ChristianaCare’s commitment to inclusion and diversity. ChristianaCare, Delaware’s largest private employer, has committed to being an anti-racism organization and works to ensure that this commitment is reflected through the organization’s policies, programs and practices. (Read more about ChristianaCare’s anti-racism commitment here.) ChristianaCare President and CEO Janice E. Nevin, M.D., MPH, has signed the CEO Action for Diversity & Inclusion Pledge. This pledge outlines a specific set of actions the signatory CEOs will take to cultivate a trusting environment where all ideas are welcomed and employees are empowered to have discussions about diversity and inclusion. More than 3,100 of ChristianaCare’s caregivers also have signed the pledge. ChristianaCare’s inclusion and diversity efforts feature 11 employee resource groups, which connect caregivers who have a common identity or bond with one another. Formed by employees across all demographics – including disability, race, military status, national origin and gender identity – these voluntary, grassroots groups work to improve inclusion and diversity at ChristianaCare. More than 1,350 caregivers participate. ChristianaCare has developed LeadershipDNA, a leadership development program that is specifically targeted to underrepresented caregivers early in their careers. ChristianaCare’s deep commitment to inclusion and diversity also includes: Providing $500,000 in scholarships to 10 high school students in Delaware who plan to pursue degrees in health care. Supporting Project Search, which is a nationally recognized program dedicated to providing education and training to young adults with intellectual and developmental disabilities. Participation in Project Hope, a partnership with external agencies that provides support to individuals who were involved with the criminal justice system. This program creates pathways to meaningful and sustainable employment within ChristianaCare. Participation in Project Veteran through career fairs that target veterans. Elimination of bias in hiring through biannual education for all hiring managers, along with leader demographic scorecards to support building a diverse workforce. Parental leave of 12 weeks for the bonding, care and wellbeing of a newborn, adopted children or foster care children. This policy applies to both birthing and non-birthing caregivers. Behavioral health services for employees that include access to professionals who specialize in mental health care and substance use disorder. A work life employee assistance program that provides free and confidential resources designed specifically for caregivers and their families. Coverage in employee health plans for gender affirmation surgery, which consists of medical and surgical treatments that change primary sex characteristics for individuals diagnosed with gender dysphoria. Autism spectrum disorders benefits – such as diagnostic assessment and treatment – to the children of caregivers who are under 21 years of age. “Our commitment to inclusion and diversity touches all areas of our organization – including our benefits packages,” said Natalie Torres, director of Inclusion & Diversity at ChristianaCare. “We know that when we offer an inclusive benefits package that anticipates the needs of our caregivers, they can better support their families and provide better care to our community.”
Cancer Program Earns Reaccreditation From the Commission on Cancer
Report cited zero deficiencies and highlights leadership, innovative programs and strong research program The Commission on Cancer, a quality program of the American College of Surgeons, has granted three-year reaccreditation to the cancer program at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, one of the original National Cancer Institute Community Cancer Centers Program sites in the U.S. ChristianaCare has received accreditation since 1951. To earn accreditation, a cancer program must meet 34 quality care standards, be evaluated every three years through a survey process and maintain levels of excellence in the delivery of comprehensive patient-centered care. The Commission cited zero deficiencies during its site visit and in its final report. “Earning this prestigious accreditation with no deficiencies cited is a testament to the unparalleled expertise and quality of care our entire team at the Graham Cancer Center provides to our patients and community across the continuum of cancer care,” said Nicholas Petrelli, M.D., Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center & Research Institute. “Patients in the communities we are privileged to serve can be assured of groundbreaking cancer treatments, innovative technology, state-of-the-art research, prevention, education and the most caring, dedicated team anywhere.” “Innovative programs that address community need” The Graham Cancer Center was recognized in the reaccreditation report for taking a multidisciplinary approach to treating cancer as a complex group of diseases that requires consultation among surgeons, medical and radiation oncologists, diagnostic radiologists, pathologists and other cancer specialists. This multidisciplinary partnership results in exceptional patient care. In its performance report, the Commission on Cancer praised the Graham Cancer Center’s leadership that has built a “culture of continual process improvement across all areas from prevention, screening, treatment and support for the patient.” It highlighted “innovative programs that address community need,” such as its on-site primary care practice and its Oncology Express Unit, which offers urgent care for patients with advanced disease. The report also stated that the “research trial offerings are a strong point.” Clinical trials test new drugs and combinations of treatments, as well as new techniques using surgery, radiation therapy, gene therapy, immunotherapy and biologics. ChristianaCare is among the national leaders in cancer clinical trials; patient enrollment rates into clinical trials at the Graham Cancer Center are at 29% which is seven times the national average. A national standard for accreditation The Commission on Cancer accreditation program provides the framework for the Graham Cancer Center to improve its quality of patient care through various cancer-related programs that focus on the full spectrum of cancer care including prevention, early diagnosis, cancer staging, optimal treatment, rehabilitation, life-long follow-up for recurrent disease and end-of-life care. When patients receive care at a Commission on Cancer-accredited facility, they also have access to information on clinical trials and new treatments, genetic counseling and patient-centered services including psycho-social support, a patient navigation process and a survivorship care plan that documents the care each patient receives and seeks to improve cancer survivors’ quality of life. Like all Commission on Cancer-accredited facilities, the Graham Cancer Center maintains a cancer registry and contributes data to the National Cancer Database, a joint program of the Commission on Cancer and American Cancer Society. This nationwide oncology outcomes database is the largest clinical disease registry in the world. Data on all types of cancer is tracked and analyzed through the database and used to explore trends in cancer care. Cancer centers, in turn, have access to information derived from this type of data analysis, which is used to create national, regional and state benchmark reports. These reports help facilities with their quality improvement efforts. Established in 1922 by the American College of Surgeons, the Commission on Cancer is a consortium of professional organizations dedicated to improving patient outcomes and quality of life for patients with cancer through standard-setting, prevention, research, education and the monitoring of comprehensive, quality care. There are currently more than 1,500 Commission on Cancer-accredited programs in the U.S. and Puerto Rico that diagnose and treat more than 70% of all patients newly diagnosed with cancer.
ChristianaCare among the top 1% of more than 4,500 hospitals nationwide For the third consecutive year, ChristianaCare has earned Healthgrades America’s 50 Best Hospitals Award™ and is among the top 1% of more than 4,500 hospitals assessed nationwide for consistent, year-over-year superior clinical performance. ChristianaCare’s Christiana Hospital and Wilmington Hospital are the only hospitals in Delaware to receive the America’s 50 Best Hospitals recognition. “At ChristianaCare, we are committed to being exceptional today and even better tomorrow. This recognition as one of America’s 50 Best Hospitals is a testament to the incredible work that our caregivers do every day to ensure safe, high-quality care and an outstanding experience for our patients,” said Janice E. Nevin, M.D., MPH, president and CEO. “I am deeply grateful for our extraordinary caregivers and for the trust we’ve earned from the communities we are privileged to serve.” ChristianaCare also received the following distinctions from Healthgrades: America’s 100 Best Hospitals for Cardiac Care Award™ for 2 years in a row (2022-2023). America’s 100 Best Hospitals for Coronary Intervention Award™ in 2023. America’s 100 Best Hospitals for Gastrointestinal Surgery Award™ for 12 years in a row (2012-2023). America’s 100 Best Hospitals for Spine Surgery Award™ for 10 years in a row (2014-2023). America’s 100 Best Hospitals for Joint Replacement Award™ for 8 years in a row (2016-2023). America’s 50 Best Hospitals for Surgical Care for 2 years in a row (2022-2023). “Achieving the prestigious Healthgrades recognition year after year after year only occurs when you have a workforce whose standard is care that is safe and of the highest quality,” said Kert Anzilotti, M.D., MBA, chief medical officer of ChristianaCare. “This recognition belongs to all the members of our clinical team, who hold themselves to the highest professional standards.” Healthgrades evaluated patient mortality and complication rates for 31 of the most common conditions and procedures at nearly 4,500 hospitals across the country to identify the top-performing hospitals. This year’s analysis revealed significant variation between America’s Best 50 Hospitals and hospitals that did not receive the distinction. In fact, if all hospitals performed similarly to America’s 50 Best, more than 150,000 lives could potentially have been saved. Patients treated for heart failure at ChristianaCare and other 2023 America’s 50 Best Hospitals have, on average, a 22.8% lower risk of dying than if they were treated at a hospital that did not receive the award.* “We’re proud to recognize ChristianaCare as one of America’s 50 Best Hospitals for 2023,” said Brad Bowman, M.D., chief medical officer and head of Data at Healthgrades. “As one of America’s 50 Best Hospitals, ChristianaCare consistently delivers better-than-expected outcomes for the patients in their community and is setting a high national standard for clinical excellence.” Visit www.Healthgrades.com/quality/americas-best-hospitals for an in-depth look at ChristianaCare’s performance and profile to explore its highest quality care. Consumers also can visit Healthgrades.com for more information on how Healthgrades measures hospital quality, and access the complete methodology here. A patient-friendly overview of the complete methodology is available here. *Statistics are based on Healthgrades analysis of MedPAR data for years 2019 through 2021 and represent three-year estimates for Medicare patients only.
For the first time in Delaware, and likely the nation, cancer specialists have co-authored a consensus statement and clinical pathway for the management of colon cancer that has spread to the peritoneum or abdominal wall. The statement has been published in the Jan. 10 online issue of Surgical Oncology. The statement aligns the state’s major health care providers on a standardized, evidence-based approach to the treatment of this kind of colon cancer. This will ensure patients throughout the state will receive optimal care and equitable access to the most appropriate treatment options and clinical trials. Medical and surgical oncologists from ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, Tunnell Cancer Center at Beebe Healthcare and TidalHealth Allen Cancer Center prepared the statement entitled, “Consensus Statement and Clinical Pathway for the Management of Colon Cancer With Peritoneal Metastases in the State of Delaware.” The statement was published on behalf of the State of Delaware Peritoneal Surface Malignancies Task Force. “Consensus among cancer specialists on how to treat colon cancer patients with peritoneal malignancy will assure that these patients have access to the specialized treatment they need at an experienced cancer center right here in Delaware,” said co-author Nicholas J. Petrelli, M.D., Bank of America endowed medical director of the Helen F. Graham Cancer Center & Research Institute. “As cancer care providers, we know how important it is for patients to be close to home for their cancer care.” “Getting cancer physicians throughout the state to agree on who is eligible for treatment and the right sequence of therapies was no small task,” said lead author Jesus Esquivel, M.D., co-director of Beebe Healthcare’s Peritoneal Surface Malignancy Program. “Thanks to Dr. Petrelli’s leadership, coupled with the support of a very committed task force, we have been able to make this happen on a statewide level.” In about 10% to 20% of cases, colon cancer is found in the peritoneum, the lining of the abdomen that covers the abdominal organs. Historically, patients with peritoneal metastases have a worse prognosis. However, numerous studies show five-year survival rates for patients whose peritoneal cancer can be surgically removed approach the rates of those with successful surgery for metastatic liver disease. “We are looking at a complicated group of patients with advanced colon cancer and a generally poor prognosis, who historically have been treated in a non-uniform fashion despite medical evidence to suggest which therapies are most effective,” Esquivel said. Combining surgery and heated chemotherapy The Delaware pathway includes a combination treatment of surgery and heated chemotherapy, starting with cytoreductive surgery (CRS) to remove all visible cancer in the peritoneum. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Mitomycin C is then delivered on the operating table for 90 minutes. Mounting clinical evidence shows this one-two punch can significantly extend survival in well-selected patients when compared with standard systemic chemotherapy. Currently, due to a steep learning curve, only about 120 hospitals in the U.S. have the necessary capability and expertise to perform these procedures. In Delaware, only ChristianaCare and Beebe Healthcare can offer patients CRS with HIPEC. Some patients who are not immediate candidates for surgery may benefit from systemic therapy (chemotherapy/immunotherapy) as a first-round treatment. Others on the pathway may be recommended for systemic therapy alone and potential participation in an appropriate clinical trial. Four-tier scoring system To help providers determine the best form of treatment for each individual patient, the Delaware pathway introduces the Peritoneal Surface Disease Severity Score (PSDSS). The scoring system uses four tiers of estimated disease severity based on a three-point scale that includes symptoms, extent of peritoneal dissemination and primary tumor histology. “With the Delaware pathway in place, our goal is to ensure that multidisciplinary evaluation begins at the time of diagnosis so that each patient is selected for the right sequence of currently available therapy depending the individual cancer,” Esquivel said. “Not only are we recommending a uniform treatment modality for patients, but our framework facilitates data reporting and evaluation that will add to the body of knowledge about this disease and how best to treat it.” Although there is plenty of medical evidence to suggest which therapies are most effective, until now, efforts by Esquivel and others to achieve consensus worldwide have not translated into a universally accepted clinical pathway for the management of this disease. Delaware is a unique launching pad for such a pathway. “As cancer care providers we know how important it is to work together on behalf of our patients,” said Petrelli. “Delaware is uniquely suited to this effort not only because of its size, but also because of the collaborative relationships we have built through groups like the Delaware Cancer Advisory Council and Consortium and most specifically for this effort, the Delaware Peritoneal Surface Malignancy Task Force.” The Delaware Health Information Network (DHIN) is another important resource to assist physician collaboration. Nearly 100% of the state’s medical providers are linked in. The DHIN launched in 2007 as the first operating statewide health information exchange in the country. “I don’t expect 100% of patients to be included in the pathway, but I see it as the best opportunity for patients to maximize benefits and minimize suffering or unnecessary treatment,” Esquivel said. “As a health care provider who treats patients with advanced cancer, I know that is the best one can hope for short of a cure. “With consensus on evidence-based clinical pathways, we can offer increasing numbers of patients the assurance that whether you live in northern or southern Delaware, you can rely on getting the best treatment available for your cancer.”
Students studying medicine, pharmacy, nursing, optometry and audiology to benefit from the investment in a new simulation facility over the next three years The Office for Students has granted Aston University £4.8 million to develop future healthcare professionals The investment in digital clinical equipment and health simulation facility will better prepare students for the future of work. Students in the College of Health and Life Sciences at Aston University are to benefit from a major £4.8 million investment in new facilities funded by the Office for Students to further expand and develop the University’s suite of state-of-the-art healthcare simulation and laboratory facilities. Students studying medicine, pharmacy, nursing, optometry and audiology will benefit from capital funding to support new equipment and facilities over the next three years. This latest funding follows on from an initial £1.5 million investment into healthcare simulation facilities on the University campus which were officially opened in December 2022 by Paulette Hamilton MP. The funds will be used to create and equip a simulated hospital ward facility and a simulated patient home environment for healthcare students. Nursing Studies is now recruiting for its first intake of students in September 2023. Pharmacy students will also gain a new wet lab and asepsis suite. The optometry simulation suite, unique in Europe, will be further enhanced with augmented reality simulation, allowing students to learn and refine their skills in a realistic instrument environment, with simulated patients with a wide range of eye conditions. Investment in other additional optometry equipment, including an additional optomap retinal screening device, will also allow the eye clinic to triage patients for the eye hospital, reducing patient waiting times, particularly in assessing conditions such as macular degeneration. Aston Medical School will be equipped with the creation of an immersive room and an anatomy and physiology teaching facility. Professor Liz Moores, Deputy Dean of the College of Health and Life Sciences, said: “The College of Health and Life Sciences is thrilled with this investment. The enhanced facilities will help to support many of our healthcare students, including those now applying for our new nursing degree. It will also support us with the introduction of the new pharmacy and optometry education standards, providing a step change in our ability to simulate a wide range of clinical scenarios.” Professor Aleks Subic, Vice-Chancellor at Aston University, said: “This strategic investment will ensure that our students are learning in the very best facilities with access to state-of-the-art digital technologies. The new facilities will enable us to prepare students fully for future careers that are strategically important to the healthcare sector and society. This is about bringing Industry 4.0 to healthcare.” Professor James Wolffsohn, Head of the School of Optometry and Audiology at Aston University, said: “With the huge hospital waiting lists, particularly post-COVID, with those in ophthalmology being the highest, it is essential that primary care can take more of the patient load to allow hospitals to focus on surgery and complex cases. This investment will allow us to better train our optometry and audiology students to be able to triage patients and to manage more conditions within community practice.” Jiteen Ahmed, Head of Technical Services in the College of Health and Life Sciences at Aston University, said: “It is fantastic to see such a large investment in our facilities to support many of our healthcare programmes. Technical staff at Aston University will be playing a key role in the design of the facilities, ensuring that we provide the most up to date and innovative technologies to meet the needs of the programmes. “I am very excited to see the involvement of technical staff as they will play a significant role in ensuring our students meet key learning outcomes in our facilities at the University.” For more information about studying in the College of Health and Life Sciences please visit our website.
Researchers awarded £2 million to develop drugs to prevent epileptic seizures in children
• Three-year research project to develop new drug treatments for childhood epilepsy • Scientists will test new treatment on pieces of living brain tissue • The research is a collaboration between Aston University, Bristol University and Jazz Pharmaceuticals. Scientists at Aston University have started work on a project that will look for new drug treatments to prevent the onset of childhood epilepsy. The three-year Medical Research Council (MRC) funded project is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, partnered with Bristol University and Jazz Pharmaceuticals. They have been awarded £2 million to explore how epilepsy becomes established in the brain and how this process might be prevented. The researchers will test new drugs in the human brain, using samples of living tissue taken from children with difficult to treat epilepsies who have had to have brain surgery. Epilepsy is a brain disease which is characterised by seizures. As Professor Gavin Woodhall, lead researcher and co-director of Aston Institute of Health and Neurodevelopment, explains: “Seizures are periods of time when networks of brain cells are too active and are uncontrollably excited and spiking. If uncontrolled excitation spreads to brain regions that control movement, then too many brain cells are ‘talking at the same time’ and we can see seizures as changes in movement such as jerks and twitches.” Upon receiving the grant, Professor Woodhall said: “We will be able to study epilepsy in such detail that we hope to be able to treat the problems that underly epilepsy and not just the seizures themselves. And this could help pave the way to prevent epilepsy from developing in children at all. “Essentially we want to find a treatment that stops the brain from being able to establish epilepsy after the first seizure - via a new drug treatment. We will be testing a known drug and a new drug to see if the drug can do this.” As part of the research for this project the scientists will look at how different amounts of epileptic activity in the brain can alter the brain’s excitability. The researchers predict that if there are a lot of seizures, the synapses in the brain will decrease their activity and brain cells will become more likely to spike. Professor Woodhall added: “This is why we will test antiepileptic drugs, and new drugs designed to interfere with homeostatic scaling - which is a form of plasticity, in which the brain responds to chronically elevated activity in a neural circuit with negative feedback, allowing individual neurons to reduce their overall action potential firing rate. “By interfering with homeostatic scaling we will be able to see if they can prevent seizures from developing or reducing their intensity.” The research will allow Professor Woodhall and his team to be able to record the life history of the disease. This is something which has not been done before in this level of detail and it is predicted it will help to shed light on how epilepsy initially develops in the brain. Following on from the three-year project the team will move into drug development and then clinical trial. For more information about research being undertaken at AIHN please go to our website. If you are interested in the courses we have available in this area please go to our course pages.